Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC

This study intends to prospectively enroll CNLC stage IIIb HCC cases with extrahepatic metastasis and intrahepatic lesions that are expected to be radical resected in several domestic clinical centers, and observe the OS and ORR, DCR, DOR, TTP and PFS of patients receiving hepatectomy combined with apatinib + carrelli pearl treatment.

Trial Details

NCT ID
NCT05062837
Phase
PHASE2 / PHASE3
Sponsor
Guangxi Medical University
Status
RECRUITING
Cancer Type
Hepatocellular Carcinoma (HCC) Liver Cancer
Interventions
  • Hepatectomy Combined With Camrelizumab and Apatinib
Locations (sample)
  • Nanning, China|22.81667,108.31667

Key Eligibility Criteria

  • CNLC stage IIIb HCC with extrahepatic metastasis (such as lymph node, lung, bone metastasis, but not brain metastasis) diagnosed by clinical imagin…
  • Local tumors of the liver are expected to be radically resected;
  • Liver function Child-Pugh grade A;
  • ICG R15 \< 10%;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hepatocellular Carcinoma (HCC) Liver Cancer Trials on Trialify →